Brunt of GST to be felt for two quarters: GSK India MD

This comes after Abbott had earlier stated that it will reimburse trade partners for losses

With the roll-out of goods and services tax (GST) around the corner, drugmakers are gearing up to make the most of the new regime. While they say they are absolutely ready for the new regime, near-term impact is what is worrying them. Speaking to Business Standard, Annaswamy Vaideesh, managing director of GlaxoSmithKline’s (GSK) India business, says that GST will benefit in the medium to long term.

When asked about worries of de-stocking, he said that the company is working with stockists to ensure they do not incur losses due to tax changes at the same time making sure there is